Trinity Biotech to Acquire Hemostasis Business

In a move to enlarge its range of hemostasis products, Trinity Biotech (Dublin, Ireland) has agreed to acquire the hemostasis division of Sigma Diagnostics (St. Louis, MO, USA), a division of Sigma-Aldrich. Terms were not disclosed.

The hemostasis business of Sigma Diagnostics comprises a comprehensive portfolio of reagents and the Amelung range of automated and semiautomated instruments manufactured in Lemgo, Germany. The reagents comprise more than 50 tests covering both routine and specialty assays. Upon completion of the transaction, Trinity intends to transfer the Sigma hemostatis test manufacturing from St. Louis to Dublin. In December 2001, Trinity acquired Biopool, another hemostasis reagent manufacturer, now transferring its test manufacturing to Dublin. The addition of Biopool's specialty tests and Sigma's tests make Trinity's range of hemostasis products complete, says the company.

"We are particularly excited about acquiring the Amelung range of hemostasis instruments that can provide automated solutions for the customer, from the physician's office to the largest reference or university laboratories, and which have a worldwide installed base of 800 instruments,” said Ronan O'Caoimh, CEO of Trinity. The company has developed and markets more than 200 diagnostic products for point-of-care testing and clinical laboratory segments of the diagnostic market.




Related Links:
Trinity Biotech
Sigma